Pharma BD Deal Intelligence
Lilly acquired Prevail Therapeutics for $1.0B upfront ($22.50/share in cash, ~$1.04B enterprise value) plus a non-tradeable CVR worth up to $4.00/share, closing January 22, 2021, to establish a neuroscience gene-therapy platform. The lead asset, PR001/LY3884961, is an AAV9 gene therapy for GBA1-mutation Parkinson's disease and neuronopathic Gaucher disease, evaluated in the Phase 1/2a PROPEL trial (NCT04127578) — still active (not recruiting) with primary completion now estimated December 2030. The thesis was a portfolio of clinical and preclinical neurodegeneration gene therapies, but it has narrowed: in February 2026 Lilly discontinued the PR006/LY3884963 program for frontotemporal dementia with progranulin mutations (PROCLAIM trial, NCT04408625) citing lack of compelling efficacy (no safety concern), as part of a broader cut of three pipeline programs. The deal remains a long-dated, early-/mid-stage neuro bet: the lead Parkinson's program is alive but pre-revenue with a 2030 readout, while one of the two named clinical assets has now failed.